Wernicke's encephalopathy in advanced gastric cancer by 源�嫄대�� et al.
VOLUME 42  NUMBER 2  JUNE  2010 77
Wernicke’s Encephalopathy in Advanced Gastric
Cancer
I n t r o d u c t i o n
Wernicke’s encephalopathy (WE) is a neurologic syndrome that
is caused by thiamine deficiency, and this is clinically characterized
by ophthalmoplegia, ataxia and acute confusion (1). It has been
underdiagnosed because WE does not always present with all these
typical symptoms. Although WE usually results from chronic alcohol
dependency, non-alcoholic causes are reported in 20% to 50% of the
cases, such as gastrointestinal (GI) tract surgery, hyperemesis
gravidarum, AIDS, chronic malnutrition, long term parenteral nutrition
and uncommonly in cancer patients (2-5). There are some case reports
of WE in malignant disease such as malignant lymphoma, acute
leukemia and breast cancer. As the exact incidence is not known due
to the lack of concern about WE, the pathophysiology of WE in
cancer patients has not been determined as well. Increased thiamine
consumption due to the rapid growth of cancer cells and inadequate
nutrition due to the nausea and anorexia from chemotherapy or
malabsorption syndrome have been suggested as possible reasons
for cancer-associated WE (6).
Patients with advanced gastric cancer (AGC) have tradionally had
a poor prognosis and short life expectancy despite aggressive
Cancer Res Treat. 2010;42(2):77-81
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
Purpose
With their prolonged survival and malnutrition, cancer patients, and especially gastrointestinal
(GI) tract cancer patients, can develop Wernicke’s encephalopathy (WE). The aim of this study
is to remind physicians of the importance of WE and prompt management in patients with GI
tract cancer.
Materials and Methods
This study is a retrospective review of 2 cases of WE in advanced gastric cancer (AGC)
patients, and we review the literature for cases of GI tract cancer related to WE.
Results
A 48-year-old female with AGC presented dizziness and diplopia for 5 days and a 20 kg
weight loss. Neurologic exam showed nystagmus and gaze disturbance. Her symptoms
improved after daily parenteral injection of thiamine 100 mg for 17 days. A 58-year-old female
with AGC presented with sudden disorientation, confusion and 15 kg weight loss. Neurologic
exam showed gaze limitation and mild ataxia. Despite daily parenteral injection of thiamine
100 mg for 4 days, she died 5 days after the onset of neurologic symptoms. Combining the
cases noted in the literature review with our 2 cases, the 7 gastric cancer cases and 2
colorectal cancer cases related to WE showed similar clinical characteristics; 1) a history of
long-period malnutrition and weight loss, 2) relatively typical neurologic signs and symptoms
and 3) specific magnetic resonance image findings. Except for 2 patients who had irre-
versible neurologic symptoms, the other 7 patients were improved with prompt thiamine
treatment.
Conclusion
It is important to consider WE in GI tract cancer patients with acute neurologic symptoms
and who are in a state of malnutrition. Thiamine should be given as soon as possible when
WE is suspected.
Key words
Wernicke’s encephalopathy, Advanced gastric cancer, Thiamine
Eun Suk Jung, M.D.1
Obin Kwon, M.D.1
Soo Hyun Lee, M.D.1,2
Ki Byung Lee, M.D.1
Joo Hoon Kim, M.D.1
Sang Hyun Yoon, M.D.1
Gun Min Kim, M.D.1
Hei-Cheul Jeung, M.D., Ph.D.1,2,3
Sun Young Rha, M.D., Ph.D.1,2,3,4
1Department of Internal Medicine, 2Yonsei
Cancer Center, 3Cancer Metastasis
Research Center, 4Brain Korea 21 Project
for Medical Science, Yonsei University
College of Medicine, Seoul, Korea
Correspondence: Sun Young Rha, M.D., Ph.D.
Department of Internal Medicine,Yonsei
University College of Medicine, 250, Seongsan-no,
Seodaemun-gu, Seoul 120-752, Korea
Tel: 82-2-2228-8050 
Fax: 82-2-362-5592
E-mail: rha7655@yuhs.ac
Received  September 25, 2009 
Accepted  October 23, 2009
This study was supported by a faculty research
grant of Yonsei University College of Medicine
for 2007.
DOI 10.4143/crt.2010.42.2.77
chemotherapy. Through the development of new chemotherapeutic
agents/regimens and the introduction of the best supportive care,
including total parenteral nutrition (TPN), there has been an in-
creased number of AGC patients who achieve long term survival.
However, there are still a significant number of AGC patients who
suffer from peritoneal carcinomatosis with or without intestinal
obstruction. Therefore, AGC patients have higher risk of chronic
malnutrition combined with cancer-specific cachexia, suggesting
they have a high risk of developing WE. Yet the cases of AGC
combined with WE are not as frequently reported as we expected and
this probably due to a lack of awareness of this combined condition.
We describe here 2 patients with WE combined with AGC and
we also review the medical literature about the clinicopathologic
features of WE in advanced GI tract cancer patients. 
R e s u l t s
1 Case 1
A 48-year-old woman with AGC (signet ring cell carcinoma) and
left ovarian metastasis (cTxNxM1, Stage IV) received 16 cycles of
paclitaxel/S-1 chemotherapy [paclitaxel 70 mg/m2 i.v. infusion day
1, 8; S-1 70 mg/m2 p.o. for 14 days, every 3 weeks] as the palliative
chemotherapy. One week after the last chemotherapy, she was ad-
mitted for nausea, vomiting and dysphagia. Obstruction of the esopha-
gogastric junction was observed on the abdomen-pelvis computed
tomography, and esophagogastric junction stent insertion was per-
formed. After stent insertion, she could tolerate a liquid diet, and she
was discharged. Two months later, however, she relapsed with
dysphagia, and so she received intermittent parenteral nutrition at
home. Her weight loss was about 20 kg during the next 2 months.
She was readmitted because of dizziness and diplopia for 5 days.
She also had nystagmus and ataxia. The laboratory findings on
admission were serum total protein 7.0 g/dL, albumin 3.5 g/dL,
BUN 22.3 mg/dL, creatinine 0.7 mg/dL, AST 18 IU/L, ALT 16
IU/L, Na 137 mmol/L, K 3.8 mmol/L, Cl 97 mmol/L, tCO2 25
mmol/L, Ca++ 4.49 mg/dL, Mg++ 1.41 mg/dL, ammonia 94 μg/dL,
PT 97% (INR 1.02) and aPTT 27.1 sec. There was no evidence of
central nervous system infection or leptomeningeal seeding. Magnetic
resonance imaging (MRI) of the brain showed high signal lesion on
the bilateral thalami, the midbrain, and the ventral side of the pons
on the flare images, and all this was compatible with WE (Fig. 1).
After 2 days of thiamine 100 mg i.v. administration, which started
on hospital day 2, her nystagmus and diplopia were improved. Seven-
teen days after thiamine injection, she was discharged from the hospital
with only mild nystagmus.
2 Case 2
A 58-year-old woman with AGC (signet ring cell carcinoma)
received subtotal gastrectomy with lymph node dissection and
gastroduodenostomy (pT3N3M0, Stage IV). She did not receive post-
operative chemotherapy because of her poor general condition.
About 6 months later, she developed metastasis to the rectus abdo-
minis muscle, omentum and liver, which was seen on abdomen-
pelvis computed tomography. After a 2nd round of palliative
FOLFOX-4 chemotherapy [oxaliplatin 100 mg/m2 i.v. infusion day
1; leucovorin 200 mg/m2 day 1�2; 5-fluorouracil (5-FU) 400 mg/m2
Cancer Res Treat. 2010;42(2):77-81
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Fig. 1. (A) Bilateral symmetric signal increase at the midbrain. (B) Bilateral symmetric signal increase at the medial part of the thalami (Flair MRI).
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i.v. bolus day 1�2; 5-FU 600 mg/m2 i.v. infusion day 1�2, every 2
weeks], she could not continue chemotherapy due to her general
weakness, anorexia, nausea, vomiting and weight loss (15 kg for 2
months). Forty-five days after the last chemotherapy, she developed
confusion and disorientation for 2 days, and this was followed by
ataxia and gaze palsy. Her laboratory findings on admission were
serum total protein 5.3 g/dL, albumin 2.8 g/dL, BUN 20.0 mg/dL,
creatinine 0.7 mg/dL, AST 16 IU/L, ALT 14 IU/L, total bilirubin
3.6 mg/dL, Na 134 mmol/L, K 4.6 mmol/L, Cl 95 mmol/L, tCO2
24 mmol/L, Ca++ 0.42 mg/dL, Mg++ 0.18 mg/dL, ammonia 53 μg/dL,
PT 81% (INR 1.15) and aPTT 40.8 sec. There was no evidence of
central nervous system infection or leptomeningeal seeding. MRI of
the brain showed high signal lesion on the bilateral thalami, the
hypothalamus and the mammillary bodies on the T2 weighted
images (Fig. 2). On hospital day 2, she also had generalized clonic
seizure. The electroencephalogram (EEG) that was taken on hospital
day 4 showed low amplitude delta background activity and no
posterior dominant rhythm. With the impression of WE, thiamine
was injected 100 mg per day on hospital day 2. She then had re-
current seizure attack and aggravation of her general condition,
which resulted in death on hospital day 6.
D i s c u s s i o n
The clinical characteristics of WE in patients with GI tract cancer,
based on the literature review and our 2 patients, are presented in
Table 1. Among the 7 gastric cancer patients, the females were more
common (n=6). The age at diagnosis ranged from 28 to 71 years
old, while more than half (n=4) were older than 65 years. WE de-
veloped in patients with or without primary gastric surgery. Almost
all the patients experienced deterioration of their general performance
and they needed parenteral nutrition. More than half of the patients
showed ataxia (n=5), nystagmus (n=4) and disorientation (n=4).
Five patients showed all the classic triad of WE: ophthalmoplegia,
ataxia and encephalopathy. Only one patient showed seizure, which
represented the disease severity from long-term thiamine deficiency.
Brain MRI was performed in five patients, and all the MRIs showed
the characteristic findings of WE. The interval from symptom
development to the start of thiamine infusion ranged from the 0 to
12 days. However, in the second case of our report, thiamine re-
placement started 3 days after the neurologic symptoms and it was
ineffective, suggesting the importance of prompt thiamine administ-
ration. In addition to the gastric cancer cases, 2 cases of WE were
reported in patients with colorectal malignancy and they had clinical
characteristics that were similar to those of the AGC patients (Table 1).
WE develops when thiamine (vitamin B1) is deficient, which is
necessary for the metabolism of carbohydrate. Thiamine is activated
as thiamine pyrophosphate and it converts pyruvate into acetyl-
CoA, which works as one of the key molecules in the tricarboxylic
acid (TCA) cycle. In WE, the thiamine deficiency results in decreased
thiamine pyrophosphate, and this deteriorates the carbohydrate
metabolism in the brain and the synaptic transmission and it triggers
damage of DNA synthesis (7). WE is clinically diagnosed by the
classic triad: ophthalmoplegia, ataxia and encephalopathy (1). Yet
WE is underdiagnosed because not all of the classic triad is presented
in many cases (8). WE is partially or fully reversible with thiamine
administration (1), but in case of delayed treatment, there is the
possibility of death within two weeks after the development of neu-
rologic symptoms (9). In our 2 cases and the 7 cases from the literature,
7 of 9 patients had improvement of their neurologic signs and
symptoms. Therefore, we should pay attention to WE in the GI tract
cancer patient with chronic malnutrition. As the proper treatment with
thiamine can easily improve the symptoms, an early diagnosis and
the early treatment of WE are important.
Fig. 2. (A) High signal lesion around the hypothalamus. (B) High signal lesion at the medial part of the thalami (T2WI MRI).
Both our reported cases showed common clinical features as
follows: 1) nutritional deficiency due to poor nutritional supplement
after chemotherapy for AGC and peritoneal carcinomatosis, 2)
deterioration of their general condition with a poor performance
status, and 3) weight loss over 12�15 kg during 2 months. Also, the
imaging studies as well as the neurologic symptoms and signs were
appropriate for WE. Including the other gastric cancer cases from
the literature review, the brain MRI findings were compatible for
WE. If WE is suspected clinically, not only a neurologic examination,
but also brain MRI are useful for making the diagnosis of WE in GI
tract cancer patients.
It is not easy to diagnose WE at the early stage in gastric cancer
patients. As the symptoms of WE are nonspecific, when AGC pa-
tients develop these symptoms, metastasis to the central nervous
system or other metabolic conditions such as drug, electrolyte im-
balance, hypoxia, uremia, sepsis, liver failure and encephalopathy
due to hypoglycemia are usually suspected first, while it is difficult
to suspect the metabolic encephalopathy from a relative nutritional
deficiency (10). Delayed encephalopathy due to 5-FU can be
considered for those patients who have received 5-FU containing
chemotherapy, although it is rare (11,12), and especially in our
second case with seizure. Yet neurologic disorders such as ophtha-
lmoplegia are rare, and high dose 5-FU infusion over 2,200 mg/m2 per
week is usually required to develop encephalopathy, so the possibility
of developing delayed encephalopathy due to 5-FU is thought to be
low (13).
Gastric cancer is the most prevalent cancer and the second highest
cause of cancer death in East Asia (14). The median overall survival
of advanced gastric cancer was 3�4 months in the past without
chemotherapy, while the median survival has recently increased to
12�13 months in several randomized clinical studies with the
newly developed chemotherapeutic agents and the best supportive
care. There is the risk of chronic weight loss and nutritional de-
ficiency associated with long term chemotherapy or longer survival.
There have been few studies concerned with or guidelines suggested
for the proper replacement of trace elements following surgery or
chemotherapy for gastric cancer. Therefore, the possibility of meta-
bolic encephalopathy, including WE, should be considered whenever
acute neurologic symptoms are developed by AGC patients who have
a poor nutritional status. It is necessary to make the early diagnosis
with imaging studies, as well as according to a neurologic examination.
Parenteral thiamine administration should not be delayed in clinically
suspected WE patients when we consider the cost-effectiveness and
few side effects such as pruritus and sweating. While there is no
consensus about intermittent prophylactic thiamine administration
for high risk patients, further studies are required to establish the
guidelines for replacement of the trace elements in these patients
with GI tract malignancy. 
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C o n c l u s i o n
As the median survival of AGC patients has been increased,
many gastric cancer patients have a poor nutritional status because
of GI tract obstruction, anorexia after chemotherapy and their poor
general condition. It is important to consider WE in AGC patients
who have acute neurologic symptoms such as ataxia, nystagmus or
disorientation. Thiamine replacement should be done as soon as
possible if a patient is diagnosed with WE.
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